by Biocross | Mar 2, 2016 | Press release
Biocross has appointed Matthew Mittino as its new CEO. Biocross is currently developing several projects centered on the diagnosis of Alzheimer’s disease and the identification of populations at risk of developing the disease. Over the last 20 years Matthew’s...
by Biocross | Nov 12, 2015 | Press release
Biocross presents a fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient stratification in clinical trials at the 2015 Clinical Trials for Alzheimer’s disease (CTAD) meeting in November 2015. Isoform E4 of...
by Biocross | Nov 20, 2014 | Press release
Biocross S.L., an innovative developer of assays for risk assessment and prediction of AD, has announced that it will be presenting a poster at the Clinical Trials on Alzheimer’s disease Conference, CTAD 2014, Philadelphia, United States, November 20-22nd, discussing...
by Biocross | Sep 29, 2014 | Press release
Biocross is involved in a new multicenter study in which 17 hospitals from Spain, France, and Belgium are participating. The objective is to recruit over 500 patients, classified as healthy individuals or patients with AD, mild cognitive impairment, or other...
by Biocross | Sep 21, 2011 | Press release
Biocross announces approval of a clinical study for the identification in blood of markers for the diagnosis of Alzheimer’s disease using a multiparametric test – September 2011 The project, entitled “Identification of markers in blood for multiparametric...
by Biocross | Jun 5, 2011 | Press release
The biotechnology spin-off Biocross is developing a laboratory test for accurate identification of Alzheimer’s disease patients. Biocross researchers are working on developing a multiparameter system, as it seems clear that a single marker is unlikely to...
